Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/25779
Title: | The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience | Authors: | BIELEN, Rob Moreno, C. Van Vlierberghe, H. Bourgeois, S. Mulkay, J. -P. Vanwolleghem, T. Verlinden, W. Brixco, C. Decaestecker, J. de Galocsy, C. Janssens, F. Van Overbeke, L. Van Steenkiste, C. D'Heygere, F. Cool, M. Wuyckens, K. Nevens, F. ROBAEYS, Geert |
Issue Date: | 2017 | Publisher: | WILEY | Source: | JOURNAL OF VIRAL HEPATITIS, 24(11), p. 976-981 | Abstract: | Recently, concerns were raised of high rates of HCC recurrence in patients treated with direct-acting antivirals (DAA) for hepatitis C infection. We investigated the HCC occurrence and recurrence rates within 6 months after treatment with DAA with or without pegylated interferon (PEG-IFN) in real life. This is a retrospective, multicenter cohort trial, executed in 15 hospitals distributed across Belgium. Populations were matched based on fibrosis score (Metavir F3-F4). Patients with a Child-Pugh score >= B were excluded. In total, 567 patients were included, of whom 77 were treated with PEG-IFN+DAA between 2008 and 2013 and 490 with DAA without PEG-IFN between 2013 and 2015. Patients treated with PEG-IFN+DAA (53 +/- 9y) were younger than patients treated with DAA without PEG-IFN (59 +/- 12y) (P=. 001). 47% of patients treated with PEG-IFN+DAA were in the F4 stage vs 67% of patients treated with DAA without PEG-IFN (P=. 001). Screening was inadequate in 20% of both patient groups (P=. 664). The early occurrence rate of HCC was 1.7% and 1.1% in patients treated with DAA with and without PEG-IFN, respectively (P=. 540). The early recurrence rate was 0% in patients treated with PEG-IFN+DAA and 15.0% in patients treated with DAA without PEG-IFN (P=. 857). There is no difference in early occurrence of new HCC between patients treated with DAA with and without PEG-IFN. We did observe a high early recurrence rate of HCC in patients treated with DAA without PEG-IFN. However, these patients were at baseline more at risk for HCC. Finally, in 20%, screening for HCC was inadequate. | Notes: | [Bielen, R.; Wuyckens, K.; Robaeys, G.] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium. [Bielen, R.; Wuyckens, K.; Robaeys, G.] Ziekenhuis Oost Limburg, Dept Gastroenterol & Hepatol, Genk, Belgium. [Moreno, C.] Erasme Univ Hosp, Dept Gastroenterol & Hepatopancreatol, Brussels, Belgium. [Van Vlierberghe, H.; Van Steenkiste, C.] Univ Hosp Gent, Dept Hepatol & Gastroenterol, Ghent, Belgium. [Bourgeois, S.] ZNA Stuivenberg, Dept Gastroenterol & Hepatol, Antwerp, Belgium. [Mulkay, J. -P.] Hop St Pierre & Erasme, Dept Gastroenterol & Hepatol, Brussels, Belgium. [Vanwolleghem, T.; Verlinden, W.] Antwerp Univ Hosp, Dept Gastroenterol & Hepatol, Edegem, Belgium. [Brixco, C.] CHR Citadelle, Dept Gastroenterol & Digest Oncol, Liege, Belgium. [Decaestecker, J.] AZ Delta, Dept Gastroenterol & Digest Oncol, Roeselare, Belgium. [Decaestecker, J.; Janssens, F.; D'Heygere, F.; Cool, M.; Nevens, F.; Robaeys, G.] Univ Hosp KU Leuven, Dept Gastroenterol & Digest Oncol, Leuven, Belgium. [de Galocsy, C.] Hop HIS Bracops, Dept Gastroenterol & Digest Oncol, Brussels, Belgium. [Janssens, F.] Jessa Hosp, Dept Gastroenterol & Digest Oncol, Hasselt, Belgium. [Van Overbeke, L.] AZ Sint Maarten, Dept Gastroenterol & Digest Oncol, Mechelen, Belgium. [Van Steenkiste, C.] AZ Maria Middelares, Dept Gastroenterol & Digest Oncol, Ghent, Belgium. [D'Heygere, F.] AZ Groeninge, Dept Gastroenterol & Digest Oncol, Kortrijk, Belgium. [Cool, M.] AZ Damiaan, Dept Gastroenterol & Digest Oncol, Oostende, Belgium. | Keywords: | direct-acting antiviral therapy; hepatitis C; hepatocellular carcinoma; pegylated interferon;direct-acting antiviral therapy; hepatitis C; hepatocellular carcinoma; pegylated interferon | Document URI: | http://hdl.handle.net/1942/25779 | ISSN: | 1352-0504 | e-ISSN: | 1365-2893 | DOI: | 10.1111/jvh.12726 | ISI #: | 000412859300008 | Rights: | © 2017 John Wiley & Sons Ltd | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2018 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
bielen 1.pdf Restricted Access | Published version | 341.06 kB | Adobe PDF | View/Open Request a copy |
HCC paper final version.pdf | Peer-reviewed author version | 153.91 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
20
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
34
checked on Jul 11, 2024
Page view(s)
64
checked on Jun 22, 2022
Download(s)
108
checked on Jun 22, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.